AddLife AB (publ) (ALIF_B) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and a warm welcome to the AdLife second quarter report. Kristina and I will take you through the highlights of the report. And after that, we will have a Q&A session as always. And as you may remember, we like to show you a little bit of a summary of some of our companies. So this time around, we are we have recorded the video with MBA, our Spanish and Portuguese company that are fantastic in orthopedic surgery. and now expanding into other fields of advanced surgery and hospital products. But let's get started now with the numbers. So I'm really pleased to share with you all that the AdLife companies continue to deliver on the priorities that we have set out. And the number one priority, as you may remember, is to improve margins and profit. So we saw a significant margin improvement in both business areas, actually, both lab tech and med tech achieving a level above 12 percent EBITDA margin, and that's a significant increase for both business areas. We saw a healthy customer demand, and the currency-adjusted sales increased by 5 percent. Organic growth was 3, and really pleased to note that we see a meaningful impact of the acquisitions we have made recently, so acquisitions contributed with 2 percent. In Labtech, we had a very strong revenue development at 9 percent, excluding currency effects. In Medtech, we had a little bit of fewer operating days, a little bit of change in product portfolio, and some reduced capital sales, but nevertheless, 4% increase excluding currency effects. So very healthy development there as well. We are working with a number of profitability improvement initiatives in a few companies. That is progressing well, but we also see that there is more potential in the future. And of course, cash flow and net debt is a ...